A clinical supply depot agreement is a short document that carries a disproportionate amount of regulatory weight. It governs where investigational medicinal product sits between manufacture and the trial site, under what conditions, with what documentation, and what happens when something goes wrong at two in the morning in a warehouse eight time zones away.
The contract itself is usually handled competently. Procurement negotiates rates and liability, quality reviews the accompanying quality agreement, legal checks the indemnities. What tends to be handled poorly is everything after signature. The commitments inside the agreement are time-bound, evidence-generating and split across three internal functions, and they are usually tracked in a combination of a logistics spreadsheet, a quality system and somebody’s memory.
This datasheet sets out what a depot agreement typically obliges, which of those obligations fail most often, and how to structure a register that clinical supply, quality and procurement can all work from. It assumes the underlying quality agreement exists and is sound, and focuses on making the commitments in both documents visible and owned.
What the agreement actually obliges
Depot agreements vary by region and provider, but the obligation categories are consistent. Each of these generates dated, evidenced duties rather than a one-time acceptance at signature.
- Storage and environmental control, defined temperature ranges by product, continuous monitoring, calibration of monitoring equipment, and documented mapping of the storage area.
- Excursion detection and notification, a defined trigger and a notification window to the sponsor, usually measured in hours, followed by investigation and disposition within a longer window.
- Regulatory authorisations, import and export licences, controlled substance registrations where applicable, and depot qualification status, each with its own expiry and renewal cycle.
- Product accountability, receipt reconciliation, quarantine handling, release to sites against authorised requests, returns processing and periodic inventory reconciliation.
- Destruction and record retention, destruction only on documented sponsor authorisation, certificates returned within a defined period, and record retention for a term that usually outlives the agreement.
Read as a list, none of these are surprising. Read as a set of dated obligations with named owners and evidence requirements, they are a substantial tracking burden that most sponsors carry informally. The same structural point applies to CRO and CMO relationships and is why obligation registers have become standard practice in life sciences obligation management rather than a nice-to-have.
Record retention and, in some jurisdictions, retention sample duties typically survive termination by a number of years defined in the agreement. An obligation register that closes out every commitment when the contract ends will quietly drop exactly the duties an inspection is most likely to test years later.
Where depot obligations fail
Failures cluster in predictable places, and in almost every case the underlying cause is that the duty had a deadline but no owner watching it.
- Excursion clocks nobody is holding. The depot detects and reports, but the sponsor-side acknowledgement, investigation and disposition each have their own windows that run unmonitored until a quality review finds them missed.
- Lapsed qualification used anyway. Requalification slips past its due date while shipments continue. The remediation is not a renewal, it is a retrospective assessment of every movement since the lapse.
- Licence conditions held only in logistics. Import licence quantity limits, expiry dates and product scope sit in a freight file rather than the obligation register, so a licence constraint is discovered at the border.
- Reconciliation performed but not evidenced. Counts are done and never documented in a form that links back to the contractual requirement, which converts a completed obligation into an audit finding.
- Destruction without documented authorisation. Product destroyed on a verbal or email approval that does not match the authorisation process the agreement specifies, leaving a gap in the accountability chain.
Standing up a depot obligation register
Step 1, Extract from both documents
Run extraction across the depot agreement and its companion quality agreement together, because the commercial and the regulated duties are deliberately split between them. Extracting one alone produces a register with visible holes, and the holes are usually on the quality side where the audit exposure is highest.
Step 2, Classify by clock type
Separate recurring duties such as periodic reconciliation and monitoring calibration from event-triggered ones such as excursion notification, and from expiry-driven ones such as licence and qualification renewal. Each type needs a different monitoring pattern, and lumping them together produces alerts nobody trusts.
Step 3, Assign a named owner per obligation
Not a function, a person, with a documented deputy. Clinical supply, quality and procurement will each own a slice. The register should make the split explicit so that an unowned obligation is visible as a gap rather than assumed to belong to someone else.
Step 4, Wire evidence to the obligation
Each completed obligation links to the artefact that proves completion: the investigation record, the reconciliation report, the destruction certificate, the renewed licence. An obligation marked complete without an evidence link is an assertion, and inspections test assertions.
Step 5, Set escalation before the deadline
Escalation timing should reflect how long remediation actually takes. A licence renewal needs warning in months, an excursion disposition in hours. Alerts that fire at the deadline itself are notifications of failure rather than controls.
One register for depot and quality commitments
See how depot obligations, owners and evidence links come together for a live trial portfolio.
Multi-depot and multi-country complications
A single-depot trial is a manageable tracking problem. A global trial running through regional depots under different local agreements, with different import regimes and different local qualification requirements, is not, and this is where informal tracking reliably fails. The obligations are structurally similar but the dates, thresholds and authorities all differ, and the sponsor needs a consolidated view of which depots are currently qualified and licensed for which products. Building that view by hand for each monitoring cycle is slow enough that it tends to be done quarterly, which is exactly the interval over which a licence lapse goes unnoticed. The same consolidation problem shows up across sponsor relationships generally, which is why teams increasingly treat depot, CRO and CMO obligations as one register rather than three.
Obligation types and monitoring patterns
The table below maps the recurring depot obligation types to the monitoring pattern each needs and the evidence that closes it. It is intended as a starting structure for a register rather than a complete clause inventory, since specific terms vary by provider and region.
| Obligation type | Clock | Typical owner | Closing evidence | Escalate before |
|---|---|---|---|---|
| Temperature excursion notification | Event-triggered, hours | Quality | Investigation and disposition record | Half the notification window |
| Depot qualification or requalification | Expiry-driven, annual cycle | Quality | Qualification report and approval | One quarter |
| Import or export licence validity | Expiry-driven, variable | Clinical supply | Current licence with scope and limits | Two months |
| Inventory reconciliation | Recurring, periodic | Clinical supply | Signed reconciliation report | One cycle |
| Destruction and certificate return | Event-triggered, days | Clinical supply with quality sign-off | Authorisation plus destruction certificate | Half the return window |
The depot agreement is not a document that rewards being filed. Its value is entirely in whether the commitments inside it are performed on time and evidenced, and that is a monitoring problem rather than a contracting one. Sponsors that pull depot and quality agreement obligations into one owned register generally find the same thing: the contracts were fine, the performance was mostly fine, and the evidence was the part that had quietly gone missing. The work to close that gap is modest, a structured extraction pass across the agreement set, a clear ownership split between clinical supply and quality, and a discipline of linking artefacts to obligations as they complete. What it buys is the ability to answer a depot question in minutes rather than assembling the answer across three systems while an inspector waits.
For related guidance, see Cold chain excursion clauses: notify, quarantine, dispose, Clinical trial site payment terms: a tracking datasheet and Comparator drug sourcing agreements: control datasheet.
